XVIVO

Conference call on Year-end Report 2024

Invitation to attend XVIVO's conference call regarding the presentation of the Year-end Report 2024. The presentation will be held in English.

Time: Tuesday, January 28, 2025, at 2.00 pm CET / 8.00 am EST

If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions. https://xvivo.events.inderes.com/xvivo-q4-report-2024

If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. Via the teleconference you can ask questions verbally. https://conference.inderes.com/teleconference/?id=5003998

Participants from XVIVO: Christoffer Rosenblad, CEO Kristoffer Nordström, CFO

The press release for XVIVO's Year-end Report 2024 will be released on January 28, 2025 at 7.30 am CET / 1.30 am EST.

Before the conference call, slides will be available at the company web page, https://www.xvivogroup. com/investors/reports-and-presentations/

January 13, 2025 Mölndal XVIVO Perfusion AB (publ)

For further information, please contact:

Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com

About Us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website www. xvivogroup.com.

XVIVO Perfusion AB, Box 530 15, SE-400 14 Göteborg. Corporate identity number 556561-0424. Tel: +46 31 788 21 50. Fax: +46 31 788 21 69. E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

Attachments

Conference call on Year-end Report 2024

XVIVO Perfusion AB, Box 530 15, SE-400 14 Göteborg. Corporate identity number 556561-0424. Tel: +46 31 788 21 50. Fax: +46 31 788 21 69. E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com